Showing results (51-60 of 82) with videos related to
Sort By:
Pageof 9
Genomics, Proteomics & Bioinformatics|March 13, 2025
The High Expression of PD-1 Defines A Subpopulation of Tfh Cells Responding to COVID-19 Vaccine in HumansJingxin Guo, Zhangfan Fu, Yi Zhang, et al.Molecular & Cellular Proteomics : MCP|April 19, 2024
Proteomic and Cellular Characterization of Omicron Breakthrough Infections and a Third Homologous or Heterologous Boosting Vaccination in a Longitudinal CohortYi Zhang, Zhangfan Fu, Haocheng Zhang, et al.International Journal of Biological Macromolecules|October 2, 2024
Aging brought additional immune response alterations after breakthrough infections with the Omicron BA.5/BF.7 variants: Protein immune mechanismYuhan Sun, Hongyu Wang, Hua Wang, et al.Journal of Infection and Public Health|December 3, 2024
Pertussis clinical profile shift, severity, prediction in a tertiary hospital: A comparative study before, during, and after COVID-19 in Southern ChinaShufeng Tian, Yulan Chen, Qiru Su, et al.Infection and Drug Resistance|March 11, 2026
Application of Droplet Digital PCR in Sputum Samples in Myasthenia Gravis Patients with PneumoniaManqiqige Su, Yeting Luo, Xiao Huan, et al.Emerging Microbes & Infections|March 17, 2026
Natural history of latent brucellosis and diagnostic performance of B-SPOT: a 24-month prospective cohort study based on large-scale screening in northern ChinaHongyu Wang, Yan O Wang, Guanmin Yuan, et al.Frontiers in Cellular and Infection Microbiology|April 12, 2021
Emergence and Autochthonous Transmission of Dengue Virus Type I in a Low-Epidemic Region in Southeast ChinaYi Zhang, Hongyi Chen, Jingen Wang, et al.Emerging Microbes & Infections|September 15, 2022
Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort studyXiaohua Chen, Hongyu Wang, Jingwen Ai, et al.Vaccines|June 27, 2025
Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I TrialHaijing Yang, Yang Zhou, Xin Cheng, et al.Virus Evolution|December 12, 2022
SARS-CoV-2 intra-host single-nucleotide variants associated with disease severityYi Zhang, Ning Jiang, Weiqiang Qi, et al.Pageof 9